CRISPR-Edited SLC30A8 Stem Cells for Type 2 Diabetes Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modeling type 2 diabetes using human induced pluripotent stem cells (iPSCs) lack efficient ways to replicate the genetic mutations associated with zinc transporter 8 (SLC30A8) variations, which are critical for understanding diabetes risk and developing therapeutic targets.
Innovation Solution
The development of human induced pluripotent stem cells with specific mutations in the SLC30A8 gene, such as R325 and R138*stop, using CRISPR/Cas9-mediated gene editing to introduce targeted mutations, allowing for the differentiation into beta-pancreatic cells and creation of animal models for diabetes research.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional iPSC modeling methods are used, then general diabetes modeling is possible, but specific genetic mutations in SLC30A8 cannot be efficiently replicated
Solution Approach 1:
The patent uses CRISPR/Cas9 gene editing to create precise copies of specific SLC30A8 mutations (R325W and R138*stop) in iPSCs, allowing accurate replication of disease-associated genetic variants that were previously difficult to model
Solution Approach 2:
The patent introduces specific genetic parameter changes (mutations) into the SLC30A8 gene using CRISPR/Cas9, transforming wild-type cells into model cells with disease-relevant genetic alterations, thereby enabling precise modeling of diabetes risk
2Manufacturing precision
If SLC30A8 mutations are introduced using traditional gene editing, then targeted mutations can be achieved, but the process is time-consuming and inefficient
Solution Approach 1:
The patent replaces traditional mechanical gene editing methods with CRISPR/Cas9-mediated editing, which uses guide RNA to direct the Cas9 enzyme to specific genomic locations, achieving faster and more efficient mutation introduction while maintaining precision
Solution Approach 2:
The patent employs guide RNA as an intermediary molecule that directs the CRISPR/Cas9 system to specific SLC30A8 mutation sites, enabling precise and efficient targeted editing without requiring complex positioning mechanisms
3Adaptability or versatility
If beta-pancreatic cells are differentiated from iPSCs, then functional cells can be obtained, but the process lacks control over specific genetic variations
Solution Approach 1:
The patent introduces SLC30A8 mutations into iPSCs before differentiation, ensuring that the genetic variations are established in the stem cell state and will be inherited by all differentiated beta-pancreatic cells, thereby maintaining genetic control throughout the differentiation process
Solution Approach 2:
The patent separates the genetic modification step from the differentiation step, first establishing the SLC30A8 mutations in iPSCs and then performing differentiation into beta-pancreatic cells, allowing independent control of genetic variation and cellular function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the generation of stem cell-derived beta-pancreatic cells that accurately model type 2 diabetes, facilitating drug screening and providing insights into the mechanisms of diabetes, potentially leading to new therapeutic and diagnostic targets.
Implementation Method 1
The cells can be generated by homologous recombination with a gene targeting construct bearing the mutation flanked by homology arms, wherein the recombination is enhanced by CRISPR/Cas9-mediated cleavage between segments of the genome corresponding to the homology arms.
Data Source
AI summary
The invention provides stem cell derived beta-pancreatic cells and animal models of T2D in which cells have been grafted. The stem cells bear a mutated form of SLC30A8 conferring protection or susceptibility to T2D. The cells and animal models can be used for drug screening as well as to provide insights into the mechanism of T2D and potentially new therapeutic and diagnostic targets.